BlueWhale Bio, Inc. has filed a notice of an exempt offering of securities to raise $15 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, BlueWhale Bio, Inc. is raising up to $15,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About BlueWhale Bio, Inc.
BlueWhale Bio is dedicated to accelerating the growth and adoption of cell-based therapies. With the demand for cell therapy products surpassing supply, BlueWhale Bio aims to address critical shortcomings in the current treatment paradigm. The company is developing a portfolio of groundbreaking products that bring the full benefits of cell therapy to more patients faster and at lower costs. For the Synecta platform, we focus on activation and expansion, as this early stage in the cell therapy manufacturing process defines which cells can be effectively processed and sets the stage for the efficiency and simplicity of all downstream steps.
To learn more about BlueWhale Bio, Inc., visit https://bluewhale.bio/
BlueWhale Bio, Inc. Linkedin Page: https://www.linkedin.com/company/bluewhale-bio/
Contact:
Peter Keller, Chief Executive Officer
617-595-7783
https://www.linkedin.com/in/peter-keller-537a17a/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.